Literature DB >> 8557269

Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.

A A Ferrando1, M Balbín, A M Pendás, F Vizoso, G Velasco, C López-Otín.   

Abstract

The human p27kip1 gene encodes a cyclin-dependent kinase inhibitor implicated in the negative regulation of the cell cycle. In order to elucidate the possible role of p27 mutations in the development or progression of human breast cancer, we have studied the occurrence of genetic abnormalities in this gene in a series of 30 primary breast carcinomas. Direct sequence analysis of the polymerase chain reaction amplified human p27 gene revealed the occurrence of two sequence variations with respect to the reported sequence; both variants were also present in the lymphocyte DNA from the same patients. First, a silent G to A change at codon 142 (Thr) was detected in a single case. Second, a T to G transversion at codon 109, resulting in a Val to Gly change, was observed in eight tumour DNA samples (26%) and in 31 out of 80 unrelated normal individuals (39%). This latter change creates a Bg/I restriction site that might be useful for genetic analysis of human tumours. Despite the occurrence of these polymorphisms, we did not however find any evidence of somatic mutations in the coding region of the p27 gene. On the basis of these results, we suggest that alterations in the integrity of the human p27 gene are not common events in human breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557269     DOI: 10.1007/bf00218840

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  25 in total

1.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 3.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

4.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.

Authors:  J M Slingerland; L Hengst; C H Pan; D Alexander; M R Stampfer; S I Reed
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

6.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

7.  Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer.

Authors:  Y J Li; P Laurent-Puig; R J Salmon; G Thomas; R Hamelin
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

8.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.

Authors:  T Mori; K Miura; T Aoki; T Nishihira; S Mori; Y Nakamura
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

9.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.

Authors:  G J Hannon; D Beach
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

10.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.

Authors:  K L Guan; C W Jenkins; Y Li; M A Nichols; X Wu; C L O'Keefe; A G Matera; Y Xiong
Journal:  Genes Dev       Date:  1994-12-15       Impact factor: 11.361

View more
  19 in total

1.  The p27/Kip1 locus shows no loss of heterozygosity in human pituitary adenomas.

Authors:  J C Wilson; J J Zhu; P M Black
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

Authors:  W Hartmann; A Waha; A Koch; C G Goodyer; S Albrecht; D von Schweinitz; T Pietsch
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation.

Authors:  W K Miskimins; G Wang; M Hawkinson; R Miskimins
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

4.  Association of CDKN1B gene polymorphisms with susceptibility to breast cancer: a meta-analysis.

Authors:  Heping Xiang; He Li; Weiwei Ge; Weidong Wu; Ming Gao; Wei Wang; Lei Hong; Datong Jiang; Changle Zhang
Journal:  Mol Biol Rep       Date:  2013-11       Impact factor: 2.316

5.  Screening of cell cycle fusion proteins to identify kinase signaling networks.

Authors:  Michelle Trojanowsky; Dusica Vidovic; Scott Simanski; Clara Penas; Stephan Schurer; Nagi G Ayad
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.

Authors:  Zhong-Ming Jia; Yan Liu; Shou-Yong Cui
Journal:  Tumour Biol       Date:  2014-02-13

7.  ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Authors:  Rebecca S Muraoka; Anne E G Lenferink; Brian Law; Elizabeth Hamilton; Dana M Brantley; L Renee Roebuck; Carlos L Arteaga
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

8.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.

Authors:  S Fredersdorf; J Burns; A M Milne; G Packham; L Fallis; C E Gillett; J A Royds; D Peston; P A Hall; A M Hanby; D M Barnes; S Shousha; M J O'Hare; X Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 9.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

10.  p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.

Authors:  Monica M Bertagnolli; Robert S Warren; Donna Niedzwiecki; Elke Mueller; Carolyn C Compton; Mark Redston; Margaret Hall; Hejin P Hahn; Scott D Jewell; Robert J Mayer; Richard M Goldberg; Leonard B Saltz; Massimo Loda
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.